Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elevation Oncology (ELEV)
NASDAQ:ELEV
Holding ELEV?
Track your performance easily
ELEV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $5.83
Previous Close$0.6
Volume896.15K
Average Volume (3M)1.34M
Market Cap
$35.67M
Enterprise Value-$44.26M
Total Cash (Recent Filing)$110.85M
Total Debt (Recent Filing)$30.92M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Oct 31, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding59,106,809
10 Day Avg. Volume640,482
30 Day Avg. Volume1,335,982
Standard Deviation0.76
R-Squared0.00710
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)0.44
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.14
Forecast
1Y Price Target
$7.67Price Target Upside1190.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Elevation Oncology News
PremiumCompany Announcements
Elevation Oncology Announces Preliminary Phase 1 Trial Results
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe 2Q24 update included 2Q opex of $11M and a quarter-end cash balance of $111M, which should support operations into 2026.
Safety ProfileThe therapy exhibited a favorable tolerability, with no grade 4 or 5 treatment-emergent adverse events.
Therapy EfficacyEO-3021 demonstrated promising potential as a targeted therapy for patients with tumors expressing Claudin 18.2.
Bears Say
Clinical DataATG-022 FiH data had the lowest ORR seen to date in this class (20%), which is an important new low anchor for the class.
Clinical Trial ResultsThe 20% ORR in all-comers represents a significant decline from partner CSPC's reported ORR of 47% in all evaluable patients within its Chinese Ph1 trial using this agent.
Stock PerformanceThe stock sold off significantly due to the small level of derisking associated with a small dataset.
---
Ownership Overview
19.97% Insiders
3.47% Mutual Funds
71.14% Other Institutional Investors
5.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELEV FAQ
What was Elevation Oncology’s price range in the past 12 months?
Elevation Oncology lowest stock price was $0.36 and its highest was $5.83 in the past 12 months.
What is Elevation Oncology’s market cap?
Currently, no data Available
When is Elevation Oncology’s upcoming earnings report date?
Elevation Oncology’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were Elevation Oncology’s earnings last quarter?
Elevation Oncology released its earnings results on Aug 06, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.224 by $0.044.
Is Elevation Oncology overvalued?
According to Wall Street analysts Elevation Oncology’s price is currently Undervalued.
Does Elevation Oncology pay dividends?
Elevation Oncology does not currently pay dividends.
What is Elevation Oncology’s EPS estimate?
Elevation Oncology’s EPS estimate is -$0.19.
How many shares outstanding does Elevation Oncology have?
Elevation Oncology has 59,106,808 shares outstanding.
What happened to Elevation Oncology’s price movement after its last earnings report?
Elevation Oncology reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.224. Following the earnings report the stock price went down -63.38%.
Which hedge fund is a major shareholder of Elevation Oncology?
Among the largest hedge funds holding Elevation Oncology’s share is Farallon Capital Management, L.L.C.. It holds Elevation Oncology’s shares valued at 10M.
---
Elevation Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (1190.81% Upside)
$7.67 (1190.81% Upside)
Blogger Sentiment
Bullish
ELEV Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 288.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.17%
12-Months-Change
Fundamentals
Return on Equity
-51.87%
Trailing 12-Months
Asset Growth
3.83%
Trailing 12-Months
Company Description
Elevation Oncology
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
---
ELEV Stock 12 Month Forecast
Average Price Target
$7.67
▲(1190.81% Upside)
Technical Analysis
Best Analysts Covering ELEV
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-4.59%
reiterated a buy rating 5 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -4.59% per trade.
---